Atrial Fibrillation

(redirected from Afib)
Also found in: Dictionary, Thesaurus, Medical, Acronyms.

Atrial Fibrillation


a cardiac arrhythmia whose basis is a disturbance in atrial activity. Atrial fibrillation often occurs with heart defects, cardiosclerosis, rheumatic endocarditis, and thyrotoxicosis, but there is no generally accepted theory to explain how it develops.

A distinction is made between paroxysmal and continuous atrial fibrillation. Continuous fibrillation may be tachyrhythmic (rapid), with a pulse of 90 to 150–180 beats per minute, or bradyrhythmic (slow), in which the pulse is never more than 60–80 beats per minute. The tachyrhythmic form is associated with sensations of palpitations, pounding, general excitement, and weakness. Patients with the bradyrhythmic form usually do not sense the arrhythmia, which is often detected only by electrocardiographic examination.

Although atrial flutter arises from the same conditions as atrial fibrillation, it is distinguished from atrial fibrillation in that the number of atrial impulses reaches 300 and the pulse may be as rapid as 240–300 beats per minute. A distinction is made between regular flutter, in which every second or third impulse travels successfully from the atria to the ventricles, and irregular flutter, in which the alternation of atrial and ventricular contractions is irregular. Atrial flutter is more difficult for patients to tolerate than is fibrillation.

Cardiac arrhythmias are treated with cardiac glycosides, quinidine, Novocainamid, Inderal, Aimalin, potassium salts, cocarboxylase, and electropulse therapy.


References in periodicals archive ?
According to a report from Medtech Insight, the Holter monitor, a device that records heart rhythms for 24-48 hours, is still the most commonly used cardiac monitor for the detection of Afib.
AFib causes the atria to flutter at a high and random rate rather than in tune with the lower ventricles, which weakens the blood flow.
We examined a range of AFib resources to identify unmet needs in the development of this shared decision making tool, and we are confident that it will complement existing resources and empower AFib patients to be more informed, active decision makers in their treatment plans," added 4WARD co-chair Christian T.
The study, called First Line Radiofrequency Ablation versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment: A Multicentre Randomized Trial (RAAFT), (LB02-1) was a multicenter, unblinded, parallel-arm clinical trial involving 127 patients with paroxysmal recurrent AFib.
Recent data in persistent AFib patients provide compelling evidence that sources are likely located outside of the pulmonary veins, the LAA being one of the most obvious.
It aims to enhance public awareness of AFib, bringing together medical experts, patient organisations and policy makers from EU Member States to create the synergies that will help address AFib efficiently and effectively.
Background Information and Anticoagulation Decision Support" is to be distributed to clinicians to improve clinician knowledge, skills and attitudes around Afib and stroke risk reduction as well as assist in anticoagulation decision-making within their workflow in either the outpatient or inpatient setting.
I sincerely thank them for contributing their time and energy to our cause and for helping better the lives of afib patients.
The primary study data published in JAMA in January 2010 demonstrated that at one year, 66% of patients treated with catheter ablation remained free from documented symptomatic AFib, compared to 16% of patients treated with medical therapy, also commonly referred to as anti-arrhythmic drugs or AADs (95% CI: 0.
AFib patients' risk for stroke is five times higher than someone without AFib.
In AFib, the LAA stops rhythmically contracting and the now non-flowing blood inside can turn to clot (a gelatin-like substance).
Since receiving the first FDA clearance for the AF Detector, an algorithm to detect AFib in an ECG, 30% of AliveCor patients have received an AFib detection.